OncoMatch/Clinical Trials/NCT06220188
PSMA-RLT in Biochemically Recurrent PCa
Is NCT06220188 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies [177Lu]Lu-PSMA I&T for prostate cancer recurrent.
Treatment: [177Lu]Lu-PSMA I&T — Prospective single-center one-arm phase II study in patients with prostate cancer and confirmed biochemical recurrence (BCR) with PSA of ≥ 0.2 ng/ml after radical prostatectomy (RP) or PSA \> nadir + 2ng/ml after radiotherapy (RT) but not radio-morphological local recurrence after primary therapy with curative intent receive systemic therapy with only 2 cycles of highly standardized (3 GBq in first cycle and 6 GBq in the second cycle) PSMA-RLT at 6-week intervals.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Biomarker criteria
Required: FOLH1 PSMA PET negative for local recurrence
PSMA PET negative result for local recurrence
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: radical prostatectomy
biochemical recurrence after radical prostatectomy
Must have received: radiotherapy
biochemical recurrence after...radiotherapy
Cannot have received: hormonal therapy
Exception: no hormonal therapy within the last 12 months or recovered testosterone levels
No hormonal therapy within the last 12 months or recovered testosterone levels
Lab requirements
Blood counts
WBC ≥1.5 x 10^9 /L, Platelets ≥100 x 10^9 /L and Haemoglobin ≥9 g/dL
Kidney function
eGFR ≥ 50mL/min/1.73m2 using the Modification of Diet Renal Disease (MDRD) equation and an Albumin level of ≥2.5 g/dL
Patients must have adequate bone marrow reserve: WBC ≥1.5 x 10^9 /L, Platelets ≥100 x 10^9 /L and Haemoglobin ≥9 g/dL. Patients must have adequate renal function with eGFR ≥ 50mL/min/1.73m2 using the Modification of Diet Renal Disease (MDRD) equation and an Albumin level of ≥2.5 g/dL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06220188 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hormonal therapy disqualifies patients from enrollment.
Does this trial require FOLH1?
Yes, FOLH1 PSMA PET negative for local recurrence is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages